The Benefits of Semaglutide: A Comprehensive Overview

Obesity represents one of the most significant global health challenges of our time, affecting over 650 million adults worldwide and contributing to numerous comorbidities including cardiovascular disease, type 2 diabetes, and nonalcoholic fatty liver disease.

Despite the cornerstone role of lifestyle interventions in weight management, sustaining meaningful weight loss over the long term remains challenging for many patients. This reality has driven the search for effective pharmacological options to complement lifestyle modifications. As research continues to unfold, the potential of semaglutide online extends far beyond glucose control, offering hope for individuals grappling with obesity, cardiovascular disease, and potentially even neurodegenerative conditions.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking advancement in obesity pharmacotherapy. Initially approved for the treatment of type 2 diabetes at doses up to 1 mg administered subcutaneously once weekly, semaglutide demonstrated promising weight reduction effects. This led to further investigation of its potential as a dedicated weight management medication at a higher dose of 2.4 mg weekly.

The FDA approval of semaglutide 2.4 mg (Wegovy) in 2021 marked a significant milestone in obesity treatment, offering patients a new option that produces weight loss approaching that of some bariatric surgical procedures. This comprehensive article examines the efficacy, safety, mechanisms of action, and clinical implications of semaglutide for weight management based on the latest research findings.

Semaglutide belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists and works through multiple pathways to induce weight loss. Understanding its mechanism of action provides insight into why it has proven so effective for weight management.

Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native human GLP-1. Its unique structural modifications allow for:

This formulation results in significantly slower degradation compared to native GLP-1's half-life of just 1-2 minutes, allowing for sustained therapeutic effects without compromising weight loss efficacy.

Semaglutide primarily promotes weight loss through its effects on the central nervous system, particularly brain regions involved in appetite regulation.

Studies in rodents have demonstrated that semaglutide exerts both direct and indirect effects on neural pathways involved in hedonic and homeostatic appetite control. This helps explain its notable impact on reducing overall energy intake.

In addition to its central effects, semaglutide influences weight loss through several peripheral mechanisms:

Importantly, research indicates that semaglutide's weight loss effects are primarily due to reduced energy intake rather than increased energy expenditure. Clinical studies show that:

Understanding semaglutide's multifaceted mechanism of action helps explain both its efficacy for weight management and its beneficial effects on various metabolic parameters beyond weight loss alone.

The Semaglutide Treatment Effect in People with Obesity (STEP) program represents a comprehensive clinical development initiative that has established the efficacy of semaglutide 2.4 mg for weight management. This section examines the robust evidence from key trials demonstrating semaglutide's effectiveness.

STEP 1 was a pivotal 68-week randomized controlled trial involving 1,961 adults with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) who did not have diabetes.

The estimated treatment difference between semaglutide and placebo was -12.4 percentage points (95% CI: -13.4 to -11.5; p<0.001). In absolute terms, participants lost an average of 15.3 kg with semaglutide compared to 2.6 kg with placebo.

STEP 2 evaluated semaglutide in 1,210 adults with type 2 diabetes, comparing 2.4 mg and 1.0 mg doses against placebo over 68 weeks.

Notably, the weight loss was approximately one-third less than observed in participants without diabetes across other STEP trials, a pattern consistent with other anti-obesity medications.

STEP 3 examined the addition of semaglutide to intensive behavioral therapy (IBT), including an initial 8-week low-calorie diet and 30 counseling sessions.

These findings suggest that semaglutide may be so effective at reducing appetite that less intensive dietary and behavioral counseling might be sufficient for many patients.

STEP 4 provided critical insights into weight maintenance and the effects of discontinuing treatment. After a 20-week run-in period where all participants received semaglutide:

This demonstrates both the continued weight loss beyond typical plateau periods and the importance of ongoing treatment for maintaining results.

STEP 5 extended treatment duration to 104 weeks to evaluate longer-term outcomes:

Results from STEP 5 confirm that weight loss with semaglutide is durable and maintained with continued treatment through two years, with no evidence of tachyphylaxis.

A systematic review and meta-analysis examining once-weekly semaglutide for weight loss found substantial reductions across multiple trials:

These comprehensive trials establish semaglutide as a uniquely effective pharmacological option for weight management, producing unprecedented levels of sustained weight loss in diverse patient populations.

Beyond its impressive weight reduction properties, semaglutide confers significant improvements across multiple cardiometabolic parameters. These beneficial effects enhance its value as a therapeutic option, particularly for patients with obesity-related comorbidities.

Across the STEP trials, semaglutide consistently demonstrated favorable effects on numerous cardiovascular risk markers compared to placebo:

These improvements in anthropometric measurements and blood pressure are clinically meaningful and could contribute to reduced cardiovascular risk.

Semaglutide demonstrated substantial benefits for glycemic parameters, even in participants without diabetes:

This suggests semaglutide may have significant potential for diabetes prevention, in addition to its established role in treating type 2 diabetes.

Semaglutide treatment led to favorable changes in lipid profiles:

These changes in lipid parameters align with the drug's overall beneficial cardiometabolic profile and may contribute to reduced cardiovascular risk.

Semaglutide significantly reduced C-reactive protein, a marker of systemic inflammation associated with cardiovascular risk:

This substantial 53% reduction in C-reactive protein suggests potential anti-inflammatory effects that may contribute to cardiovascular risk reduction.

Dual-energy X-ray absorptiometry (DXA) data from subpopulations in the trials revealed important insights into body composition changes:

These favorable changes in body composition may contribute to the metabolic benefits observed with semaglutide treatment.

While dedicated cardiovascular outcome trials with semaglutide 2.4 mg for obesity are ongoing (SELECT trial), data from the SUSTAIN-6 trial with semaglutide 0.5-1.0 mg in patients with type 2 diabetes showed promising cardiovascular benefits:

Beyond biochemical improvements, semaglutide significantly enhanced health-related quality of life and physical functioning:

These improvements in patient-reported outcomes reflect the real-world impact of treatment on daily functioning and quality of life.

The comprehensive cardiometabolic benefits observed with semaglutide extend well beyond weight loss alone, positioning it as a multifaceted therapeutic option that addresses numerous aspects of obesity-related health impairments.

While semaglutide's efficacy for weight loss is impressive, a comprehensive understanding of its safety profile is essential for clinical decision-making and patient counseling. This section examines the adverse events associated with semaglutide 2.4 mg for weight management based on data from clinical trials.

Clinical trials report similar overall incidence of adverse events between semaglutide and placebo groups, though with notable differences in specific event types:

Gastrointestinal disorders represent the most common adverse events with semaglutide treatment:

The most frequently reported gastrointestinal events included:

Gallbladder-Related Disorders

Gallbladder-related disorders, particularly cholelithiasis (gallstones), were more common with semaglutide than placebo:

This increased incidence is consistent with previous findings for other GLP-1 receptor agonists and with the known effects of rapid weight loss on gallbladder function. The absolute risk remains relatively low but warrants clinical attention.

The higher incidence of serious adverse events with semaglutide (9.8% vs. 6.4% with placebo) was primarily attributed to:

Most other categories of serious adverse events showed similar rates between treatment groups.

Acute pancreatitis, a concern with GLP-1 receptor agonist class, was rare but did occur in a small number of participants:

Semaglutide, like other GLP-1 receptor agonists, is associated with modest increases in heart rate:

Despite these pulse rate changes, cardiovascular outcomes data from SUSTAIN-6 suggest overall cardiovascular safety and potential benefit.

Hypoglycemia was rare in participants without diabetes:

Fatal events were uncommon and balanced between groups:

Discontinuation due to adverse events was more common with semaglutide than placebo (7.0% vs. 3.1%), with gastrointestinal disorders being the primary reason:

Several factors may influence the risk of adverse events with semaglutide:

The safety profile of semaglutide 2.4 mg for weight management appears generally consistent with that observed at lower doses for type 2 diabetes, with gastrointestinal disorders representing the predominant concern. Most adverse events are transient, mild-to-moderate in severity, and manageable with appropriate clinical guidance.

Semaglutide 2.4 mg weekly represents an important advancement in the pharmacological treatment of obesity. This section explores practical aspects of its use, patient selection, and optimal integration into comprehensive weight management programs.

Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management in adults who meet specific criteria:

Ideal candidates for semaglutide therapy typically include:

Proper dosing and administration are critical for optimizing efficacy while minimizing adverse effects:

The recommended dose escalation protocol:

Semaglutide should be used as an adjunct to, not a replacement for, lifestyle interventions:

The STEP trials demonstrated varying intensities of lifestyle intervention combined with semaglutide:

Interestingly, the intensive behavioral therapy in STEP 3 added only modest additional weight loss compared to the simpler approach in STEP 1, suggesting that semaglutide's appetite-suppressing effects may reduce the need for intensive behavioral support in some patients.

Regular monitoring of patients on semaglutide is essential for assessing efficacy, safety, and need for dose adjustments:

Special considerations apply to certain patient populations:

Semaglutide is contraindicated in:

Weight management with semaglutide typically requires long-term treatment. Data from STEP 4 demonstrated substantial weight regain when semaglutide was discontinued after 20 weeks:

Practical implementation of semaglutide therapy requires addressing economic factors:

Healthcare providers should discuss these practical considerations with patients before initiating therapy to set realistic expectations and develop sustainable treatment plans.

The appropriate use of semaglutide 2.4 mg requires thoughtful patient selection, careful dose titration, regular monitoring, and integration with lifestyle interventions to maximize benefits while minimizing risks and costs.

To fully appreciate semaglutide's role in obesity management, it's essential to compare it with other available treatment options. This section examines how semaglutide 2.4 mg compares to alternative pharmacotherapies, bariatric surgery, and lifestyle interventions, helping clinicians and patients make informed treatment decisions.

Semaglutide 2.4 mg demonstrates superior efficacy compared to other FDA-approved anti-obesity medications:

Liraglutide 3.0 mg daily is the only other GLP-1 receptor agonist approved for weight management. The STEP 8 trial directly compared weekly semaglutide 2.4 mg with daily liraglutide 3.0 mg:

Beyond superior efficacy, semaglutide offers the convenience of once-weekly versus once-daily administration, potentially improving treatment adherence.

Bariatric surgical procedures have historically been the most effective interventions for severe obesity. Comparing semaglutide 2.4 mg with typical surgical outcomes:

While bariatric surgery typically produces greater average weight loss, semaglutide offers:

Lifestyle interventions remain the foundation of obesity treatment but often produce modest and transient results:

Semaglutide's 15% mean weight loss substantially exceeds what most patients achieve with lifestyle interventions alone. Importantly, the STEP trials demonstrated that semaglutide enhanced the effectiveness of concurrent lifestyle interventions:

Different weight management approaches carry distinct safety considerations:

Emerging research is exploring combinations of semaglutide with other interventions:

The optimal approach to obesity management should be individualized based on multiple factors:

Semaglutide 2.4 mg represents a significant advancement in the obesity treatment landscape, offering efficacy that bridges the gap between traditional pharmacotherapy and bariatric surgery. Its introduction expands the treatment continuum, providing clinicians and patients with more options to tailor approaches to individual needs, preferences, and circumstances.

The development of semaglutide 2.4 mg for obesity represents a significant milestone, but active research continues to expand our understanding and optimize treatment approaches. This section explores ongoing trials, emerging formulations, and future directions in obesity pharmacotherapy.

One of the most anticipated ongoing studies is the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) trial:

The SELECT trial will be followed by SELECT-LIFE, an observational non-interventional study examining long-term effects for up to 10 years after the SELECT trial ends. These studies will provide critical data on whether semaglutide's weight reduction translates to meaningful cardiovascular risk reduction in patients without diabetes.

Several STEP trials are examining semaglutide's efficacy and safety in specific populations:

These trials will help define appropriate use in populations not well-represented in the primary registration trials.

Research is exploring alternative formulations of semaglutide to improve convenience and potentially expand treatment options:

Promising developments include:

The future of obesity pharmacotherapy likely involves combination approaches:

A key area of ongoing research involves optimizing strategies for long-term weight maintenance after initial semaglutide-induced weight loss:

Current research is investigating factors that might predict response to semaglutide:

Beyond clinical efficacy, research is addressing practical aspects of semaglutide implementation:

Ongoing research continues to explore semaglutide's mechanisms of action:

As clinical use of semaglutide 2.4 mg expands, real-world evidence will complement clinical trial data:

Research is beginning to examine the potential population-level impacts of widespread semaglutide adoption:

The rapid pace of innovation in obesity pharmacotherapy suggests that semaglutide 2.4 mg, while representing a significant advancement, may be just the beginning of a new era in which pharmacological options provide efficacy approaching that of bariatric surgery with significantly less invasiveness. Ongoing research will continue to refine our understanding of how to optimize the use of these powerful new tools in the management of obesity.

The emergence of semaglutide 2.4 mg as a treatment for obesity represents a paradigm shift in pharmacological weight management. This comprehensive review of clinical evidence provides several key insights that collectively highlight semaglutide's transformative impact on obesity treatment.

Semaglutide has demonstrated unprecedented efficacy for a non-surgical obesity intervention:

The availability of semaglutide 2.4 mg has several important implications for clinical practice:

Despite its impressive efficacy, several practical challenges must be addressed for optimal implementation of semaglutide therapy:

The decision to use semaglutide must consider its complete benefit-risk profile:

For many patients with obesity—particularly those with weight-related comorbidities—the benefits of treatment are likely to outweigh the risks when appropriate patient selection, monitoring, and management of side effects are implemented.

Semaglutide 2.4 mg represents an important advancement in a rapidly evolving field:

As research continues with next-generation agents (tirzepatide, retatrutide, oral formulations), the obesity treatment landscape is likely to further expand, potentially offering even greater efficacy and convenience. These developments reinforce the shift toward viewing obesity as a treatable chronic disease rather than simply a lifestyle issue.

Semaglutide 2.4 mg weekly represents a significant milestone in obesity pharmacotherapy, providing clinically meaningful weight reduction and associated health benefits. Its introduction has fundamentally altered the therapeutic algorithm for obesity management, creating a middle ground between lifestyle intervention and bariatric surgery.

While not a universal solution and not without limitations, semaglutide offers hope to many patients struggling with obesity and expands the toolkit available to clinicians. When integrated appropriately within comprehensive care models that include lifestyle intervention, careful patient selection, and ongoing monitoring, semaglutide has the potential to significantly impact individual and potentially population health outcomes related to obesity.

The journey toward optimal obesity management continues, but semaglutide represents a substantial step forward in this ongoing pursuit.

[1] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi: 10.1056/NEJMoa2032183.

[2] Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi: 10.1016/S0140-6736(21)00213-0.

[3] Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. doi: 10.1001/jama.2021.1831.

[4] Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi: 10.1001/jama.2021.3224.

[5] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4.

[6] Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. doi: 10.1001/jama.2021.23619.

[7] Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino DM. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050-1061. doi: 10.1002/oby.22794.

[8] Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Klein S, Le Roux CW, Pi-Sunyer X, Rubino DM, Wilding JPH; STEP 1 Investigators. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. doi: 10.1016/j.ahj.2020.07.008.

[9] Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201-223. doi: 10.1038/s41573-021-00337-8.

[10] Chao AM, Quigley KM, Wadden TA. Obesity in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2023;176(6):857-865. doi: 10.7326/M22-1964.

[11] Moiz A, Kandhi S, Makary MS, Tarar MNN, Amine S, Siddiqui AH, Ullah W, Fischman DL, Cohen MG, Moiz O. Meta-analysis of efficacy, safety and cardiovascular outcomes with semaglutide for treatment of obesity in adults. Am J Cardiol. 2024;203:38-47. doi: 10.1016/j.amjcard.2023.12.017.

[12] Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs. 2015;75(9):935-945. doi: 10.1007/s40265-015-0410-1.

[13] Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752. doi: 10.1056/NEJMoa066254.

[14] Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163-2171. doi: 10.1002/oby.20584.

[15] Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4.

[16] Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161. doi: 10.2337/diacare.27.1.155.

[17] Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056/NEJMoa1411892.

[18] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.

[19] Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023. doi: 10.1016/j.jacc.2013.11.004.

[20] Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi: 10.1056/NEJMoa2206038.

[21] Kahan S, Garvey WT. The pharmacotherapy of obesity—new and promising agents. Nat Rev Endocrinol. 2023;19(3):142-158. doi: 10.1038/s41574-023-00786-8.

[22] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi: 10.1056/NEJMoa2107519.

[23] Novo Nordisk. Novo Nordisk achieves primary objective of the SELECT cardiovascular outcomes trial with Wegovy demonstrating a statistically significant and superior reduction in major adverse cardiovascular events. Company Announcement. 8 August 2023. https://www.novonordisk.com/content/dam/nncorp/global/en/news-archive/2023/company-announcement-08082023.pdf

[24] Davies M, Aroda VR, Collins BS, Garvey WT, McCann J, Rosenstock J, Thorsted BL, Luo Y, Kushner RF; STEP HFpEF Investigators. Efficacy and safety of semaglutide 2.4 mg once weekly in patients with heart failure with preserved ejection fraction and obesity: the STEP HFpEF randomized clinical trial. Circulation. 2023;148(23):1822-1833. doi: 10.1161/CIRCULATIONAHA.123.064825.

[25] Chao AM, Tronieri JS, Amaro A, Wadden TA. Clinical management of weight regain after bariatric surgery. Surg Obes Relat Dis. 2021;17(1):229-238. doi: 10.1016/j.soard.2020.09.018.

[26] Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, De la Rosa R, Woo VC, Larsen CM, Storgaard H, Bjerre Knudsen L, Gough SCL. Superior weight loss with once-weekly semaglutide versus daily liraglutide in adults with overweight or obesity: a post hoc analysis of the STEP 8 randomized clinical trial. Diabetes Obes Metab. 2022;24(8):1613-1619. doi: 10.1111/dom.14736.

[27] Batterham RL, Tomas E, Rosenstock J, Kelly K, Frias JP. Efficacy and safety of an oral semaglutide once-daily tablet versus subcutaneous semaglutide once-weekly injection for weight management: the OASIS 1 phase 3a trial. Presented at: ObesityWeek; November 12-15, 2023; Dallas, TX.

[28] Jastreboff AM, Guo H, Drevets D, Jiménez Murillo D, Young V, Laddu AA, Brøndsted L, Lim S, Rubino DM; SURMOUNT-4 Investigators. Continued tirzepatide versus placebo to maintain weight loss. N Engl J Med. 2023;389(18):1671-1685. doi: 10.1056/NEJMoa2307539.

[29] Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Huet F, Marcus C, Mehdiyoun NR, Poitou Bernert C, Pyle L, Stoica O, Tamborlane WV, Weghuber D, Arslanian SA. Liraglutide for weight management in adolescents with obesity: a randomized controlled trial. N Engl J Med. 2020;382(22):2117-2128. doi: 10.1056/NEJMoa1916038.

[30] Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 Suppl 3:1-203. doi: 10.4158/EP161365.GL.

Recommended dose escalation:

Initial 4 weeks: 0.25 mg once weekly Weeks 5-8: 0.5 mg once weekly Weeks 9-12: 1.0 mg once weekly Weeks 13-16: 1.7 mg once weekly Week 17 and onward: 2.4 mg once weekly (maintenance dose)

Administration instructions:

Administer subcutaneously in the abdomen, thigh, or upper arm Inject on the same day each week, at any time of day, with or without meals If a dose is missed and the next scheduled dose is more than 2 days away (>48 hours), administer as soon as possible If a dose is missed and the next scheduled dose is less than 2 days away (≤48 hours), skip the missed dose and administer on the regular scheduled day

Special populations:

No dose adjustment required for mild-to-moderate renal impairment Limited experience in severe renal impairment; use with caution No dose adjustment required for mild-to-moderate hepatic impairment Not recommended in severe hepatic impairment Safety and efficacy not established in pediatric patients

Modified dosing for intolerance:

If unable to tolerate a dose during dose escalation, consider delaying dose escalation by 4 weeks If unable to tolerate the 2.4 mg maintenance dose, may decrease to 1.7 mg once weekly For persistent intolerance, consider slower dose escalation (8 weeks at each step rather than 4)

Storage:

Refrigerate at 2°C to 8°C (36°F to 46°F) May store at room temperature (below 30°C/86°F) for up to 28 days Do not freeze Protect from light